Samsung Bioepis

News

Will Gottlieb follow up on Trump's promise of a bonfire of regulations?

FDA begins review of Samsung Bioepis/Biogen's Lucentis biosi...

Novartis/Genentech’s eye drug Lucentis could be the next big blockbuster to face competition from cheaper biosimilars after its US patent expired this year – and Samsung Bioepis and Biogen

News

FDA approves Samsung/Merck & Co's Herceptin biosimilar

The FDA has approved a new biosimilar of Roche’s breast cancer drug Herceptin, from Samsung Bioepis and Merck & Co, ahead of the original drug’s US patent expiry in June.

News

Samsung Bioepis' Humira biosimilar launches in EU

Samsung Bioepis has become the latest biosimilars company to confirm it has launched a cheaper near-copy of AbbVie’s Humira inflammatory diseases blockbuster, after its European patent expi

News

Merck & Co signs biosimilars deal for US veterans

Merck & Co has signed a deal with the US Department of Veterans Affairs (VA) for its inflammatory diseases biosimilar, Renflexis, so that veterans’ care can be improved.

News